Amylyx Pharmaceuticals (AMLX) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 103.3% versus a gain of 74.8%. Amylyx Pharmaceuticals is the larger company by market cap ($3.44 billion vs $3.08 billion), about 1.1 times the size, while Arcus Biosciences is growing revenue faster (-4.3% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | RCUS |
|---|---|---|
| Share price | $27.43 | $24.52 |
| Market cap | $3.44B | $3.08B |
| 1-day change | -2.18% | +0.99% |
| YTD return | +127.07% | +2.90% |
| 1-year return | +103.34% | +74.77% |
| 5-year return | — | -28.70% |
| EPS (TTM) | $-1.41 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $247.00M |
| Revenue growth (YoY) | -100.00% | -4.26% |
| Net income (latest FY) | $-144.74M | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $41.14 | $31.74 |
| 52-week low | $10.83 | $14.26 |
| Distance from 52-week high | -33.33% | -22.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +54.43% | +62.77% |
| Average volume | 2.33M | 1.32M |
| Shares outstanding | 125.51M | 125.77M |
| Employees | 136 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed RCUS by 28.6 percentage points over the past year.
- Arcus Biosciences grew revenue faster in its latest fiscal year (-4.26% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
AMLX vs RCUS FAQ
Which is bigger, Amylyx Pharmaceuticals or Arcus Biosciences?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.44B compared with $3.08B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, AMLX or RCUS?
AMLX returned +103.34% over the past 12 months, compared with +74.77% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.